5-acetamido-4-(3-(furan-2-ylmethyl)ureido)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid | 1392414-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 5-acetamido-4-(3-(furan-2-ylmethyl)ureido)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
• 英文别名: (2R,3R,4S)-3-acetamido-4-(furan-2-ylmethylcarbamoylamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
• CAS: 1392414-92-4
• 化学式: C₁₇H₂₃N₃O₉
• 分子量: 413.384
• InChiKey: JJZBKPYFWMPUOM-PWRGDLIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  191
• 氢给体数：
  7
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  methyl 5-acetamido-4-(3-(furan-2-ylmethyl)ureido)-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以75%的产率得到5-acetamido-4-(3-(furan-2-ylmethyl)ureido)-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid
  参考文献：
  名称：

  Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities

  摘要：

  With the introduction of bioisosteres of the guanidinium group together with scaffold hopping, 35 zanamivir analogs with C-4-modification were synthesized, and their inhibitory activities against both group-1 and group-2 neuraminidase (H5N1 and H3N2) were determined. Compound 026 exerts the most potency, with IC50 values of 0.58 and 2.72 mu M against N2 and N1, respectively. Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts similar to 58% protective against AIV infection, which was comparable to zanamivir (similar to 67%). In a rat pharmacokinetic study, compound D5 showed an increased plasma half-life (t(1/2)) compared to zanamivir following either intravenous or oral administration. This study may represent a new start point for the future development of improved anti-AIV agents. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.06.033

文献信息

• Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities
  作者：Deju Ye、Woo-Jin Shin、Ning Li、Wei Tang、Enguang Feng、Jian Li、Pei-Lan He、Jian-Ping Zuo、Hanjo Kim、Ky-Youb Nam、Weiliang Zhu、Baik-Lin Seong、Kyoung Tai No、Hualiang Jiang、Hong Liu

  DOI：10.1016/j.ejmech.2012.06.033

  日期：2012.8

  With the introduction of bioisosteres of the guanidinium group together with scaffold hopping, 35 zanamivir analogs with C-4-modification were synthesized, and their inhibitory activities against both group-1 and group-2 neuraminidase (H5N1 and H3N2) were determined. Compound 026 exerts the most potency, with IC50 values of 0.58 and 2.72 mu M against N2 and N1, respectively. Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts similar to 58% protective against AIV infection, which was comparable to zanamivir (similar to 67%). In a rat pharmacokinetic study, compound D5 showed an increased plasma half-life (t(1/2)) compared to zanamivir following either intravenous or oral administration. This study may represent a new start point for the future development of improved anti-AIV agents. (C) 2012 Elsevier Masson SAS. All rights reserved.